Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Mar 2015
At a glance
- Drugs Semaglutide (Primary) ; Semaglutide
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 20 Jul 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 20 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.